Category: Education
-
Short answer: A new MD Anderson study in appendiceal adenocarcinoma shows why looking beyond mutations matters. DNA testing found the KRAS mutation that made the tumors a target. Single-cell RNA sequencing then showed what the tumor cells and the cells around them did when KRAS was blocked, something no mutation report can tell you. If…
-
Short answer: Most people with appendix cancer who make the CRS/HIPEC decision don’t regret it. Caregivers carry a heavy load, though, and their regret is higher when their loved one dies. That comes from three studies: a 2024 patient study and a 2025 caregiver study from the University of New Mexico, and Yale’s DECISIVE study,…
-
Short answer: A fistula after CRS/HIPEC is an abnormal connection that forms after surgery. This article focuses mainly on enterocutaneous fistulas, where the bowel connects to the skin and bowel contents drain through an opening in the abdomen. In one large study of pseudomyxoma peritonei (PMP) patients, 2.4% developed an intestinal fistula. Some close without…
-
In the metformin PMP webinar on September 22, 2026, Dr. Oliver Eng of UC Irvine answered patient questions about his trial of metformin for pseudomyxoma peritonei (PMP). He covered who can join, the five in-person visits, cost, side effects, and whether patients taking palbociclib or a KRAS inhibitor can join. I hosted the session and…
-
BromAc appendix cancer treatment works best in one specific situation: an isolated large mucinous tumor, generally at least 5 cm across, that a radiologist can reach with a drain, in a person who is otherwise holding up reasonably well. When the disease is spread across the whole abdomen, the drug thins out through the cavity…
-
An intestinal transplant for PMP is an option for a small number of carefully selected people whose pseudomyxoma peritonei can no longer be removed with conventional surgery and whose disease has caused severe intestinal or nutritional failure. A 2025 conference report from the Oxford Transplant Centre found that most people referred for it arrive too…